新诊断炎症性肠病患者的管理方法:成人及儿童胃肠病学家的使用指南
本文综述了新诊断克罗恩病和溃疡性结肠炎的管理策略,强调早期诊断和及时治疗是改善预后的关键。文章提出基于临床、人口学和血清学标志物的风险分层指导一线治疗选择,并主张采用客观终点确认缓解(达标治疗)和通过替代生物标志物持续控制炎症(紧密控制)。此外,强调药物治疗之外的预防保健、营养和心理行为支持等综合管理。
要点
- 早期诊断和及时治疗是改善IBD预后的基石,需降低疑诊门槛并在初级诊疗层面识别预警信号。
- 基于临床、人口学和血清学标志物的风险分层有助于指导一线治疗选择。
- 达标治疗需用客观终点确认缓解,紧密控制需用替代生物标志物调整治疗。
核心结论
- 早期诊断和及时治疗是改善IBD结局和最大化健康的核心。
- 风险分层可指导一线治疗选择,达标治疗和紧密控制是确认和维持缓解的重要策略。
- IBD管理远超越药物治疗,需整合预防保健、营养和心理行为支持。
研究设计与样本
- 本文为综述,聚焦新诊断IBD患者的管理方法,面向成人及儿童胃肠病学家。
主要发现
- IBD是慢性、进展性、免疫介导的疾病,无法治愈,可导致狭窄、瘘管、感染和癌症等并发症。
- 儿童IBD还可导致生长障碍和青春期延迟。
- IBD诊断延迟(尤其是克罗恩病)常见且与不良结局相关。
- 许多患者对治疗无应答,一线治疗选择至关重要。
- 临床决策支持工具、基因组学和其他生物标志物是未来个性化医学的方向。
临床怎么用
- 在初级诊疗层面保持低疑诊门槛并识别预警信号,以指导早期专科转诊。
- 基于临床、人口学和血清学标志物进行疾病严重度风险分层以指导一线治疗。
- 开始适当治疗后,用客观终点确认缓解(达标治疗),并用替代生物标志物调整治疗以持续控制炎症(紧密控制)。
- 关注预防保健、营养和心理行为支持,处理患者对补充治疗和用药依从性的关切,预防残疾并确保开放沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic, progressive, immune-mediated diseases of adults and children that have no cure. IBD can cause significant morbidity and lead to complications such as strictures, fistulas, infections, and cancer. In children, IBD can also result in growth impairment and pubertal delays. IBD is highly heterogenous, with severity ranging from mild to severe and symptoms ranging from mild to debilitating. Delay in IBD diagnosis, especially in Crohn's disease, is common and associated with adverse outcomes. Early diagnosis and prompt institution of treatment are the cornerstones for improving outcomes and maximizing health. Early diagnosis requires a low threshold of suspicion and red flags to guide early specialist referral at the primary provider level. Although the armamentarium of IBD medications is growing, many patients will not respond to treatment, and the selection of first-line therapy is critical. Risk stratification of disease severity, based on clinical, demographic, and serologic markers, can help guide selection of first-line therapy. Clinical decision support tools, genomics, and other biomarkers of response to therapy and risk of adverse events are the future of personalized medicine. After starting appropriate therapy, it is important to confirm remission using objective end points (treat to target) with continued control of inflammation with adjustment of therapy using surrogate biomarkers (tight control). Lastly, IBD therapy extends far beyond medications, and other aspects of the overall health and wellbeing of the patient are critical. These include preventive health, nutrition, and psychobehavioral support addressing patients' concerns around complementary therapy and medication adherence, prevention of disability, and ensuring open communication.
引用
- Agrawal M, Spencer EA, Colombel JF, et al. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021. PMID: 33940007. doi:10.1053/j.gastro.2021.04.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。